Pharmaceutical News

RSS

WellWorld Science officially launches Livea in the U.S.

After more than 30 years of research and an extensive open-label weight loss study, WellWorld Science® announces the official U.S. launch of Livea®, a doctor-developed, non-prescription, patent-pending appetite-control supplement that is unlike any other dietary supplement on the market.

27 Jan 2010

NIST researchers determine best practices for storing and monitoring refrigerated vaccines

Every year, billions of dollars worth of vaccines are shipped to thousands of medical providers across the country, and every year doctors must dispose of tens of millions of dollars worth of those vaccines because they became too warm or too cold while in storage.

27 Jan 2010

Spectrum Pharmaceuticals discontinues the development of ozarelix in BPH

Spectrum Pharmaceuticals, a commercial-stage biotechnology company with a primary focus in oncology, today announced that it is discontinuing development of ozarelix in benign prostatic hypertrophy (BPH).

27 Jan 2010

Acyclovir reduces occurrence of HSV-2 genital ulcers but does not affect HIV transmission

Research from a five-year international clinical study shows that acyclovir, a commonly prescribed drug used to suppress symptoms of the herpes virus, does not affect HIV transmission by people with both viruses.

27 Jan 2010

MU researcher develops EFdA compound that is more potent than current HIV therapies

With the help of effective drug therapies, HIV patients are living longer, healthier lives. Now, researchers want to improve these drug therapies and develop alternative preventative strategies, such as vaginal gels and creams that contain the same or related compounds used in treatments for people infected with HIV.

27 Jan 2010

Researchers identify new drugs to protect brain cells from neurological disease

Researchers have identified a compound that mimics one of the brain's own growth factors and can protect brain cells against damage in several animal models of neurological disease.

27 Jan 2010

USAN approves generic name "ulimorelin" for Tranzyme Pharma's TZP-101

Tranzyme Pharma today announced that the United States Adopted Name Council (USAN) has approved the generic name “ulimorelin” for Tranzyme’s novel, late-stage, prokinetic agent TZP-101. Ulimorelin, if approved, is expected to be a first-in-class drug for the treatment of gastrointestinal (GI) dysmotility indications in acute care (hospital-based) settings.

27 Jan 2010

Jubilant Biosys, Endo Pharmaceuticals expand their drug discovery partnership in oncology

Jubilant Biosys Ltd., a subsidiary of Jubilant Organosys Ltd., and Endo Pharmaceuticals ( ENDP)., of Chadds Ford, Pa., U.S.A., announced today that they have expanded their drug discovery partnership in oncology, following the successful delivery of an early stage milestone.

27 Jan 2010

Counterfeit version of Alli sold over the Internet: FDA warns

FDA is alerting consumers to an unsafe, counterfeit version of the weight-loss drug Alli sold over the Internet.

27 Jan 2010

USPTO grants Cenestra Health patent relating to high-purity omega-3 fatty acid formulations

Cenestra Health announced today that the U.S. Patent and Trademark Office has issued a key patent related to the company's high-purity omega-3 fatty acid formulations and their methods of use. U.S. Patent No. 7652068, entitled "Omega-3 Fatty Acid Formulations," covers a unique, high-purity formulation of the omega-3 fatty acids EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid).

27 Jan 2010

Potential risk factors in skipping insulin injections

More than half of people with diabetes who take insulin injections to control their diabetes say they have intentionally skipped an injection, with one-fifth of them reporting that they do so "sometimes" or "often," according to a study being published this month in Diabetes Care.

27 Jan 2010

Study: PROSTVAC-VF vaccine effective in treating patients with metastatic prostate cancer

In a newly published clinical trial, patients with metastatic prostate cancer who received a vaccine of harmless poxviruses engineered to spur an immune system attack on prostate tumor cells lived substantially longer than patients who received a placebo vaccine, report researchers at Dana-Farber Cancer Institute and affiliated organizations.

27 Jan 2010

Asan Medical Center, Chemizon enter into multi-year research collaboration agreement

Asan Medical Center and Chemizon, the drug discovery division of Optomagic, Co. Ltd., announced today that they have entered into a multi-year research collaboration to discover and develop novel, small molecule oncology therapeutics.

27 Jan 2010

FDA recalls Huber infusion set needles

The U.S. Food and Drug Administration today announced a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets, manufactured by Nipro Medical Corporation for Exelint International Corporation.finf

27 Jan 2010

Fibromyalgia drug to earn 38% patient share in the U.S. and 30% patient share in Europe

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a fibromyalgia drug that improves sleep quality more than Pfizer's Lyrica would earn a 38 percent patient share in the U.S. and a 30 percent patient share in Europe due to its efficacy, safety and tolerability, and delivery.

27 Jan 2010

U.S. court decision favors Teva in generic Temodar ANDA litigation

Teva Pharmaceutical Industries Ltd. announced today that the U.S. District Court for the District of Delaware has issued a decision in its litigation over the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Schering-Plough’s brain tumor treatment Temodar® (temozolomide). The Court found that U.S. Patent No. 5,260,291 is not enforceable due to prosecution laches and inequitable conduct.

27 Jan 2010

Health Canada approves first post-surgical treatment for patients with gastrointestinal stromal tumours

Patients with gastrointestinal stromal tumours (GIST) can now take action at an earlier stage of this rare form of cancer to reduce the risk of their disease returning following surgery. Novartis Pharmaceuticals Canada announced today that Gleevec* (imatinib mesylate) has received conditional approval by Health Canada for the adjuvant (post-surgical) treatment of adult patients who are at intermediate to high risk of disease recurrence following the surgical removal of GIST.

27 Jan 2010

FDA approves the NDA of Roxane Laboratories' Morphine Sulfate Oral Solution CII

Roxane Laboratories, Inc. announced today the New Drug Application (NDA) approval of Morphine Sulfate Oral Solution CII, 100mg/5mL (20mg/mL) 30mL and 120mL bottles as of January 25th, 2010 by the Food and Drug Administration.

27 Jan 2010

Women on antidepressant drugs may experience lactation difficulties

According to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM), women taking commonly used forms of antidepressant drugs may experience delayed lactation after giving birth and may need additional support to achieve their breastfeeding goals.

27 Jan 2010

Sumavel DosePro and Levadex to earn up to $400M by 2018

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Zogenix/Astellas Pharma/Desitin Pharmaceuticals' needle-free Sumavel DosePro, which launched earlier this month in the United States, and MAP Pharmaceuticals' orally-inhaled Levadex will earn approximately $400 million in combined sales by 2018 in the migraine drug market.

27 Jan 2010

Pharmaceutical News

WellWorld Science officially launches Livea in the U.S.

NIST researchers determine best practices for storing and monitoring refrigerated vaccines

Spectrum Pharmaceuticals discontinues the development of ozarelix in BPH

Acyclovir reduces occurrence of HSV-2 genital ulcers but does not affect HIV transmission

MU researcher develops EFdA compound that is more potent than current HIV therapies

Researchers identify new drugs to protect brain cells from neurological disease

USAN approves generic name "ulimorelin" for Tranzyme Pharma's TZP-101

Jubilant Biosys, Endo Pharmaceuticals expand their drug discovery partnership in oncology

Counterfeit version of Alli sold over the Internet: FDA warns

USPTO grants Cenestra Health patent relating to high-purity omega-3 fatty acid formulations

Potential risk factors in skipping insulin injections

Study: PROSTVAC-VF vaccine effective in treating patients with metastatic prostate cancer

Asan Medical Center, Chemizon enter into multi-year research collaboration agreement

FDA recalls Huber infusion set needles

Fibromyalgia drug to earn 38% patient share in the U.S. and 30% patient share in Europe

U.S. court decision favors Teva in generic Temodar ANDA litigation

Health Canada approves first post-surgical treatment for patients with gastrointestinal stromal tumours

FDA approves the NDA of Roxane Laboratories' Morphine Sulfate Oral Solution CII

Women on antidepressant drugs may experience lactation difficulties

Sumavel DosePro and Levadex to earn up to $400M by 2018

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News